Genetics and Causality of Triglyceride-Rich Lipoproteins in Atherosclerotic Cardiovascular Disease

被引：204

作者：

Rosenson, Robert S. ^{[1
]}

Davidson, Michael H. ^{[2
]}

Hirsh, Benjamin J. ^{[3
]}

Kathiresan, Sekar ^{[4
]}

Gaudet, Daniel ^{[5
,6
]}

机构：

[1] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[2] Univ Chicago, Pritzker Sch Med, Div Cardiol, Chicago, IL 60637 USA

[3] Mt Sinai Hosp, New York, NY 10029 USA

[4] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA

[5] Univ Montreal, Dept Med, ECOGENE 21, Chicoutimi, PQ, Canada

[6] Univ Montreal, Dept Med, Lipid Clin, Chicoutimi, PQ, Canada

来源：

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2014年 / 64卷 / 23期

关键词：

atherosclerosis; cardiovascular disease; genetics; triglyceride; triglyceride-rich lipoproteins; LOW-DENSITY-LIPOPROTEIN; CORONARY-HEART-DISEASE; APOLIPOPROTEIN C-III; ALIPOGENE TIPARVOVEC AAV1-LPLS447X; TISSUE-SPECIFIC EXPRESSION; CYTOSOLIC LIPID DROPLETS; GENOME-WIDE ASSOCIATION; EXTENDED-RELEASE NIACIN; NONFASTING TRIGLYCERIDES; SEVERE HYPERTRIGLYCERIDEMIA;

D O I：

10.1016/j.jacc.2014.09.042

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Triglycerides represent 1 component of a heterogeneous pool of triglyceride-rich lipoproteins (TGRLs). The reliance on triglycerides or TGRLs as cardiovascular disease (CVD) risk biomarkers prompted investigations into therapies that lower plasma triglycerides as a means to reduce CVD events. Genetic studies identified TGRL components and pathways involved in their synthesis and metabolism. We advocate that only a subset of genetic mechanisms regulating TGRLs contribute to the risk of CVD events. This " omic" approach recently resulted in new targets for reducing CVD events. (C) 2014 by the American College of Cardiology Foundation.

引用

页码：2525 / 2540

页数：16

共 50 条

[21] Triglyceride and Triglyceride-Rich Lipoproteins in Atherosclerosis
Zhang, Bai-Hui
Yin, Fan
Qiao, Ya-Nan
Guo, Shou-Dong
FRONTIERS IN MOLECULAR BIOSCIENCES, 2022, 9
[22] TRIGLYCERIDE-RICH LIPOPROTEINS AND ATHEROSCLEROSIS
SCHWANDT, P
DRUGS, 1990, 40 : 38 - 41
[23] ATHEROGENICITY OF TRIGLYCERIDE-RICH LIPOPROTEINS
SHEPHERD, J
CASLAKE, M
GAW, A
GRIFFIN, B
LINDSAY, G
PACKARD, C
ANNALES DE BIOLOGIE CLINIQUE, 1993, 51 (3-5) : 260 - 262
[24] Hyperinsulinemia and triglyceride-rich lipoproteins
Steiner, G
Lewis, GF
DIABETES, 1996, 45 : S24 - S26
[25] TRIGLYCERIDE-RICH LIPOPROTEINS AND ATHEROSCLEROSIS
PATSCH, JR
ATHEROSCLEROSIS, 1994, 110 : S23 - S26
[26] Atherogenicity of triglyceride-rich lipoproteins
Krauss, RM
AMERICAN JOURNAL OF CARDIOLOGY, 1998, 81 (4A): : 13B - 17B
[27] TRIGLYCERIDE-RICH LIPOPROTEINS AND ATHEROSCLEROSIS
SCHWANDT, P
FORTSCHRITTE DER MEDIZIN, 1985, 103 (26) : 683 - 685
[28] Complexity of triglyceride-rich lipoprotein remnant cholesterol with atherosclerotic cardiovascular disease risk
Santos, Raul D.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2023, 30 (11) : 1139 - 1141
[29] Triglyceride-Rich Lipoproteins and Novel Targets for Anti-atherosclerotic Therapy
Reiner, Zeljko
KOREAN CIRCULATION JOURNAL, 2018, 48 (12) : 1097 - 1119
[30] Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes
Abdel-Maksoud, Madiha
Sazonov, Vasilisa
Gutkin, Stephen W.
Hokanson, John E.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2008, 51 (04) : 331 - 351

← 1 2 3 4 5 →